The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.
 
Ryan D. Gentzler
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst)
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck; Takeda
Research Funding - Advantagene (Inst); Ariad (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Stem CentRx (Inst)
Other Relationship - Amgen; Lilly; Peregrine Pharmaceuticals; Synta
 
Hossein Borghaei
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genmab; Lilly; Merck; Novartis; Pfizer; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - University of Pennsylvania
 
Shirish M. Gadgeel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer
Speakers' Bureau - AstraZeneca
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; Genentech/Roche
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck; Nektar
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Vyriad (Inst)
 
Renato G. Martins
Research Funding - Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
James Stevenson
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
 
Shadia Ibrahim Jalal
Research Funding - AstraZeneca/MedImmune
 
Amit W. Panwalkar
Research Funding - Merck (Inst)
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Hansoh; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Yuhan
 
Matthew A. Gubens
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Mersana; Novartis
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst)
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - Bristol-Myers Squibb
 
Joseph Fiore
Employment - Merck Sharp & Dohme
 
Sanatan Saraf
Employment - Merck Sharp & Dohme
 
Steven M. Keller
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Leena Gandhi
Consulting or Advisory Role - AstraZeneca; Hengrui Pharmaceutical ; Ignyta; Merck Sharp & Dohme; Roche/Genentech; Syndax
Research Funding - Bristol-Myers Squibb